PTC Therapeutics (PTCT) PT Raised to $78 at Morgan Stanley

Morgan Stanley analyst Jeffrey Hung raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $78.00 (from $71.00) while maintaining a Overweight rating.

The analyst comments "We update our model for the quarter based on 3Q25 actuals and management commentary. Our price target moves to $78 (from $71 previously), with the increase driven by roughly equal contributions from our model rollforward, OpEx adjustments, and higher Sephience estimates. Our price target is derived from a discounted cash flow analysis assuming a 10% discount rate and 0.5% terminal growth post-2035."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• MaxLinear (MXL) PT Raised to $105 at Stifel
• TEN Holdings (XHLD) files for 8M share offering